Frequently Asked Questions

  • Are safety precautions being taken due to COVID-19?

    Yes, all GATHER2 trial site doctors are taking precautions and addressing COVID-19 concerns by pre-screening participants before visits, performing temperature checks upon arrival, providing personal protective equipment (PPE) for each visit, and enforcing social distancing.

    In addition, the trial sponsor will provide a private car service at no cost to you for transportation to and from your trial visits.

    The driver will be wearing PPE and the vehicle will be cleaned prior to picking you up. More information can be found at COVID-19 Precautions.

  • AMD is an aging disease of the eye.

    As it progresses, it may become difficult to read, drive or recognize faces.

    Geographic atrophy is a more advanced stage of macular degeneration. It generally affects both eyes and gets worse as one continues to age.

    Currently there are no approved treatments available for geographic atrophy. There are US Food and Drug Administration (FDA)–approved treatments for the wet form of AMD.

    Visit About GA Associated with AMD to learn more.

  • Visit our Resources & Support section to access links to organizations that can help you learn more about managing and living with AMD and GA.

  • Currently, there are no approved treatment options available for patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).

    Participating in the GATHER2 Clinical Trial will help find out whether a potential treatment option, known as Zimura® (avacincaptad pegol), could help patients with GA secondary to AMD.

    Most prescription medications must be tested in a clinical trial before they are available to the general public. Clinical trials evaluate the safety and effectiveness of drugs by enrolling a certain number of people.

    Participants in a clinical trial are generally monitored very closely.

    Participation in a clinical trial helps develop new therapies that may potentially improve the lives of people with a disease or condition similar to your disease or condition.

    Read more about clinical trials at About Clinical Trials.

  • GATHER2 is a phase 3 trial testing a potential treatment option known as Zimura® (avacincaptad pegol).

    Phase 3 refers to the final phase of testing typically required for a treatment to be approved by the regulatory agency (FDA).

    The trial will find out whether Zimura® is safe and can help slow down the progression of geographic atrophy (GA).

    Learn more About the GATHER2 Clinical Trial.

  • Participants in the GATHER2 trial will be treated and followed for 2 years.

    Learn more at About the GATHER2 Clinical Trial.

  • Yes, your privacy is protected while participating in the GATHER2 Clinical Trial.

    The research professionals cannot tell anyone about your participation unless you tell them it’s okay to do so, and your name will not be listed in any reports written about the trial.

    All of the information gathered in the trial is strictly confidential.

    Learn how your privacy is protected at About Clinical Trials.

  • We’ve put together a list of questions to help you talk to your eye doctor about the GATHER2 Clinical Trial.

    Please download our Doctor Discussion Guide and bring it with you to your next appointment.

  • Yes. There was a GATHER1 Clinical Trial, which was similar to GATHER2.

    GATHER1 was an 18-month phase 3 clinical trial assessing Zimura® as a potential treatment for geographic atrophy (GA). Approximately 300 people participated in the GATHER1 Clinical Trial.

    Talk to your eye doctor to learn more about the GATHER1 Clinical Trial.

  • Talk to your eye doctor if you are interested in participating in this trial.

    Please call 1-833-ZIMURA2 (1-833-946-8722) toll-free at any time. A representative will take your call between 9:00 AM and 5:00 PM Eastern Time, Monday through Friday.

    If you call after hours or during the weekend, please leave a message and we will attempt to return your call by the next business day.

    You may be eligible to participate in GATHER2 if you have been diagnosed with geographic atrophy (GA). If you are diagnosed with age-related macular degeneration (AMD) but are unsure whether you have GA, you may still be eligible to participate.

    Learn more about GATHER2 Participation Requirements.

  • Learn about the Participation Requirements. Or contact us for more information.

  • GATHER2 has a number of trial site locations throughout the United States and Canada.

  • Yes, you or your trial doctor may choose to stop and/or end your participation at any time for any reason.

  • You do not have to pay for participating in the GATHER2 Clinical Trial. The sponsor, IVERIC bio, Inc., will provide the study treatment and pay for all the trial procedures.

    In addition, the sponsor will provide you and/or a companion with travel services and a stipend for your participation.

    Please speak to the trial staff for more details.


Zimura® (avacincaptad pegol) is a registered trademark of IVERIC bio, Inc.